Grace Therapeutics
GRCE · Nasdaq · United States
Share price · GRCE
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when GRCE's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 28 Oct 2026+7.5%
Nothing announced by GRCE that day or the session before.
- 26 Oct 2026-6.2%
Nothing announced by GRCE that day or the session before.
- 14 Oct 2026-5.0%
Nothing announced by GRCE that day or the session before.
- 10 Sep 2026+5.6%
Nothing announced by GRCE that day or the session before.
- 23 Apr 2026-45.5%
- 14 Apr 2026+12.0%
Nothing announced by GRCE that day or the session before.
- 7 Apr 2026-18.2%
Nothing announced by GRCE that day or the session before.
- 6 Apr 2026-20.7%
Nothing announced by GRCE that day or the session before.
- 30 Mar 2026-6.6%
Nothing announced by GRCE that day or the session before.
- 17 Feb 2026+9.1%
Nothing announced by GRCE that day or the session before.
Share of unusual movement by asset
For each asset, the share of GRCE's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
Nimodipine (GTx-104)events and moves
| 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 19% |
| Other company news (earnings, financing, releases naming no asset) | — | 11% |
| Sessions with no dated event | — | 70% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | L-type calcium channels (Cav1.2)Small molecule | Subarachnoid Hemorrhage |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $0.9M | $21M | $2.1M-$1.8M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $0.7M | $14M | $16M-$3.2M operating cash flow | report ↗ |
| 2025-Q4 | — | $0.5M | $19M | $2.3M-$2.2M operating cash flow | report ↗ |
| 2025-Q3 | — | $0.6M | $17M | $0.9M-$3.1M operating cash flow | report ↗ |
| 2025-Q2 | — | $1.0M | $20M | $3.4M-$1.8M operating cash flow | report ↗ |
| 2024-Q4 | — | $2.2M | $11M | $4.2M-$4.1M operating cash flow | report ↗ |
| 2024-Q3 | — | $3.0M | $15M+ <$0.1M short-term inv. | $3.4M-$4.2M operating cash flow | report ↗ |
| 2024-Q2 | — | $2.7M | $19M+ <$0.1M short-term inv. | $2.6M-$3.6M operating cash flow | report ↗ |
| 2023-Q4 | — | $1.4M | $19M+ $6.6M short-term inv. | $2.4M-$1.9M operating cash flow | report ↗ |
| 2023-Q3 | — | $0.5M | $27M+ <$0.1M short-term inv. | $3.3M-$2.1M operating cash flow | report ↗ |
| 2023-Q2 | — | $1.1M | $22M+ <$0.1M short-term inv. | $4.0M-$6.2M operating cash flow | report ↗ |
| 2022-Q4 | — | $2.5M | $26M+ $5.0M short-term inv. | $3.9M-$3.7M operating cash flow | report ↗ |
| 2022-Q3 | — | $3.3M | $35M+ <$0.1M short-term inv. | $4.9M-$3.4M operating cash flow | report ↗ |
| 2022-Q2 | — | $2.6M | $38M+ <$0.1M short-term inv. | $4.5M-$5.4M operating cash flow | report ↗ |
| 2021-Q4 | $0 | $2.2M | $33M+ $13M short-term inv. | $3.8M-$4.6M operating cash flow | report ↗ |
| 2021-Q3 | — | $0.6M | $37M+ $14M short-term inv. | —-$6.1M operating cash flow | report ↗ |
Annual history (6 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-FY | — | $2.4M | $17M | $1.9M-$8.9M operating cash flow | report ↗ |
Grace Therapeutics reported R&D spend of $2.4M, down 74.8% YoY, cash and equivalents of $16.98M, and a net loss of $7.79M for fiscal year 2026.
Figures only: this period's report disclosed no narrative text
View 5 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $9.5M | $22M | $2.4M-$15M operating cash flow | report ↗ |
| 2024-FY | — | $4.7M | $23M+ $0 short-term inv. | $3.2M-$12M operating cash flow | report ↗ |
| 2023-FY | — | $10.0M | $28M+ <$0.1M short-term inv. | $11M-$16M operating cash flow | report ↗ |
| 2022-FY | $0 | $5.6M | $30M+ $13M short-term inv. | $2.5M-$17M operating cash flow | report ↗ |
| 2021-FY | $0.2M | $4.2M | $51M+ $9.8M short-term inv. | $4.9M-$14M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 27 purchases ($923K), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-18 | Opaleye Management Inc. · 10% owner | Open-market purchase | 2,974 | $1.73 | $5K | Form 4 |
| 2026-11-17 | Opaleye Management Inc. · 10% owner | Open-market purchase | 29,207 | $1.72 | $50K | Form 4 |
| 2026-11-16 | Opaleye Management Inc. · 10% owner | Open-market purchase | 15,879 | $1.76 | $28K | Form 4 |
| 2026-11-05 | Opaleye Management Inc. · 10% owner | Open-market purchase | 3,087 | $1.77 | $5K | Form 4 |
| 2026-11-04 | Opaleye Management Inc. · 10% owner | Open-market purchase | 5,027 | $1.80 | $9K | Form 4 |
| 2026-11-03 | Opaleye Management Inc. · 10% owner | Open-market purchase | 10,328 | $1.79 | $18K | Form 4 |
| 2026-10-26 | Opaleye Management Inc. · 10% owner | Open-market purchase | 66,411 | $1.77 | $117K | Form 4 |
| 2026-10-22 | Opaleye Management Inc. · 10% owner | Open-market purchase | 21,390 | $1.93 | $41K | Form 4 |